OmniAbOABI +3.15%72 Buyback Yield % is 0.00 as of Jul. 12, 2026. GuruFocus rates OABI with a GF Score™ of 72/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 3 warning signs investors should review. Among 742 Biotechnology companies, OmniAb ranks worse than 134770.75% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for OmniAb's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OABI vs VNDA, AVIR, UPB: Buyback Yield % Comparison
For the Biotechnology subindustry, OmniAb's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OmniAb Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OmniAb's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where OmniAb's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OmniAb (OABI) has a Buyback Yield % of 0.00 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OmniAb and its competitors. According to the industry distribution chart, OmniAb ranks #999999 out of 742 companies in the Biotechnology industry.
Is OmniAb's Buyback Yield % too high?
OmniAb's current Buyback Yield % is 0.00. Based on the distribution chart, OmniAb ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OmniAb has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's Buyback Yield % compare to VNDA and AVIR?
According to the Biotechnology industry distribution chart, OmniAb ranks #999999 out of 742 companies for Buyback Yield %. This places OmniAb in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OmniAb and its competitors. OmniAb's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.30 — trading 1.3% above its estimated fair value. The current Buyback Yield % is 0.00. OmniAb's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For OmniAb (OABI), the current Buyback Yield % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OmniAb (OABI) Overvalued in 2026?
Based on GuruFocus' analysis, OmniAb stock appears to be overvalued.
The current stock price of $2.30 is trading 1.3% above its estimated GF Value™ of $2.27.
GuruFocus considers OmniAb to be Fairly Valued.
Key valuation signals for OABI:
Buyback Yield %: 0.00
GF Value™: $2.27 vs. price of $2.30 (1.3% above fair value)
No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
72GF Score
Get the complete analysis for OABI
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OABI has been successfully added to your 
